Artesunate-dapsone-proguanil treatment of falciparum malaria: Genotypic determinants of therapeutic response

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 99, Issue 2, 2005, Pages 142-149

  Krudsood, Sivicha ^a   Imwong, Mallika ^a   Wilairatana, Polrat ^a   Pukrittayakamee, Sasithon ^a   Nonprasert, Apichart ^a   Snounou, Georges ^b   White, Nicholas J ^a,c   Looareesuwan, Sornchai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b INSTITUT PASTEUR   (France)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Antifol; Artesunate; Dapsone; Plasmodium falciparum; Proguanil; Thailand

Indexed keywords

ARTESUNATE; CHLORPROGUANIL PLUS DAPSONE; DAPSONE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; MEFLOQUINE; PROGUANIL;

ABDOMINAL DISCOMFORT; ADULT; AFRICA; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; MALARIA FALCIPARUM; MALE; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; THAILAND; TREATMENT FAILURE; TREATMENT OUTCOME; WILD TYPE;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHLOROGUANIDE; DAPSONE; DIHYDROPTEROATE SYNTHASE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES; RECURRENCE; SESQUITERPENES; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM;

EID: 11144323302     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2004.07.001     Document Type: Article

References (34)

1. S. Biswas A. Escalante S. Chaiyaroj P. Angkasekwinai A.A. Lal Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: A molecular epidemiologic study Trop. Med. Int. Health. 5 2000 737-743
2. P.B. Bloland P.N. Kazembe A.J. Oloo B. Himonga L.M. Barat T.K. Ruebush Chloroquine in Africa: Critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa Trop. Med. Int. Health. 3 1998 543-552
3. A. Brockman R.E. Paul T.J. Anderson I. Hackford L. Phaiphun S. Looareesuwan F. Nosten K.P. Day Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand Am. J. Trop. Med. Hyg. 60 1999 14-21
4. J. Curtis M.T. Duraisingh D.C. Warhurst In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulphadoxine but not chlorproguanil-dapsone treatment J. Infect. Dis. 177 1998 1429-1433
5. J. Curtis C.A. Maxwell F.H. Msuya S. Mkongewa A. Alloueche D.C. Warhurst Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment J. Infect. Dis. 186 2002 1861-1864
6. M.T. Duraisingh J. Curtis D.C. Warhurst Plasmodium falciparum: Detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion Exp. Parasitol. 89 1998 1-8
7. S.J. Foote A.F. Cowman The mode of action and the mechanism of resistance to antimalarial drugs Acta Trop. 56 1994 157-171
8. I. Hastings W.M. Watkins N.J. White Pharmacokinetic parameters affecting the evolution of drug-resistance in malaria; the role of the terminal elimination half-life Philos. Trans. R. Soc. Lond. B. Biol. Sci. 357 2002 505-519
9. M. Hekmat-Nejad P.K. Rathod Plasmodium falciparum: Kinetic interactions of WR99220 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase Exp. Parasitol. 87 1997 222-228
10. M. Imwong S. Pukrittayakamee S. Looareesuan G. Pasvol J. Poirriez N.J. White G. Snounou Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulphadoxine/pyrimethamine: Geographical and clinical correlates Antimicrob. Agents Chemother. 45 2001 3122-3127
11. J.G. Kublin F.K. Dzinjalamala D.D. Kamwendo E.M. Malkin J.F. Cortese L.M. Martino R.A. Mukadam S.J. Rogerson A.G. Lescano M.E. Molyneux P.A. Winstanley P. Chimpeni T.E. Taylor C.V. Plowe Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria J. Infect. Dis. 185 2002 380-388
12. H.M. McIntosh P. Olliaro Treatment of uncomplicated malaria with artemisinin derivatives. A systematic review of randomised controlled trials Med. Trop. (Mars) 58 1998 57-58
13. T.K. Mutabingwa C.A. Maxwell I.G. Sia F.H. Msuya S. Mkongewa S. Vannithone J. Curtis C.F. Curtis A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania Trans. R. Soc. Trop. Med. Hyg. 95 2001 433-438
14. T. Mutabingwa A. Nzila E. Mberu E. Nduati P. Winstanley E. Hills W. Watkins Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania Lancet. 358 2001 1218-1223
15. S. Nair J.T. Williams A. Brockman L. Paiphun M. Mayxay P.N. Newton J.P. Guthmann F.M. Smithuis T.T. Hien N.J. White F. Nosten T.J. Anderson A selective sweep driven by pyrimethamine treatment in SE Asian malaria parasites Mol. Biol. E vol.20 2003 1526-1536
16. F. Nosten M. van Vugt R. Price C. Luxemburger A. Brockman R. McGready F. ter Kuile S. Looareesuwan N.J. White Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study Lancet. 356 2000 297-302
17. A.M. Nzila E. Nduati E.K. Mberu S.C. Hopkins S.A. Monks P.A. Winstanley W.M. Watkins Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum J. Infect. Dis. 181 2000 2023-2028
18. D.S. Peterson D. Walliker T.E. Wellems Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria Proc. Natl. Acad. Sci. USA 85 1988 9114-9118
19. C.V. Plowe J.F. Cortese A. Djimde O.C. Nwanyanwu W.M. Watkins P.A. Winstanley J.G. Estrada-Franco R.E. Mollinedo J.C. Avila J.L. Cespedes D. Carter O.K. Doumbo Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance J. Infect. Dis. 176 1997 1590-1596
20. W. Sirawaraporn P. Prapunwattana R. Sirawaraporn Y. Yuthavong D.V. Santi The dihydrofolate reductase domain of Plasmodium falciparum thymidylate synthase-dihydrofolate reductase: Gene synthesis, expression, and anti-folate resistance mutants J. Biol. Chem. 268 1993 21644-21673
21. V.A. Snewin S.M. England P.F.G. Sims J.E. Hyde Characterisation of the dihydrofolate reductase-thymidylate synthase gene from human malaria parasites highly resistant to pyrimethamine Gene. 76 1989 41-52
22. J. Sulo P. Chimpeni J. Hatcher J.G. Kublin C.V. Plowe M.E. Molyneux K. Marsh T.E. Taylor W.M. Watkins P.A. Winstanley Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: A randomised clinical trial Lancet. 360 2002 1136-1143
23. T. Triglia A.F. Cowman The mechanism of resistance to sulfa drugs in Plasmodium falciparum Drug Resist. Updat. 2 1999 15-19
24. T. Triglia J.G. Menting C. Wilson A.F. Cowman Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum Proc. Natl. Acad. Sci. USA 94 1997 13944-13949
25. M. van Vugt E. Leonardi L. Phaipun T. Slight K.L. Thway R. McGready A. Brockman L. Villegas S. Looareesuwan N.J. White F. Nosten Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil Clin. Infect. Dis. 35 2002 1498-1504
26. P. Wang M. Read P.F. Sims J.E. Hyde Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization Mol. Microbiol. 23 1997 979-986
27. W.M. Watkins M. Mosobo Treatment of Plasmodium falciparum malaria with pyrimethamine-sulphadoxine: Selective pressure for resistance is a function of long elimination half-life Trans. R. Soc. Trop. Med. Hyg. 87 1993 75-78
28. W.M. Watkins A.D. Brandling-Bennett C.G. Nevill J.Y. Carter D.A. Boriga R.E. Howells D.K. Koech Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum infection in Kenya Trans. R. Soc. Trop. Med. Hyg. 82 1988 398-403
29. N.J. White Antimalarial drug resistance: The pace quickens J. Antimicrob. Chemother. 30 1992 571-585
30. N.J. White Antimalarial drug resistance and combination chemotherapy Philos. Trans. R. Soc. Lond. B Biol. Sci. 354 1999 739-749
31. P. Wilairatana D.E. Kyle S. Looareesuwan K. Chinwongprom S. Amradee N.J. White W.M. Watkins Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand Ann. Trop. Med. Parasitol. 91 1997 125-132
32. P. Winstanley W. Watkins D. Muhia S. Szwandt E. Amukoye K. Marsh Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: Pharmacokinetics and therapeutic range Trans. R. Soc. Trop. Med. Hyg. 91 1997 322-327
33. WHO Severe and complicated malaria Trans. R. Soc. Trop. Med. Hyg. 84 Suppl 2 1990
34. WHO, 2002. Monitoring Antimalarial Drug Resistance. Report of a WHO Consultation. World Health Organization, Geneva, WHO/CDS/CSR/EPH/2002.17.